Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Flonase suit

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline has dropped its lawsuit disputing FDA's approval of generic Flonase (fluticasone propionate). GSK decided not to appeal the March 6 ruling of Baltimore federal court Judge Andre Davis that denied the firm's request for a preliminary injunction on the sale of the generic nasal spray. FDA's approval of the generic nasal spray Feb. 22 prompted GSK to file suit; the court granted the firm a temporary restraining order suspending FDA approval of the drug until March 6 (1"The Tan Sheet" Feb. 27, 2006, p. 4). GSK discontinued plans for an Rx-to-OTC switch of Flonase in favor of pursuing legal action against the sale of generics, and now says it has no plans to resume a switch program...

You may also be interested in...

Flonase Generic Launch Blocked; Glaxo Drops Switch Plan

GlaxoSmithKline has shelved an OTC switch of Flonase nasal steroid as a competitive strategy in favor of litigation to block generics

The Good, The Bad And The Ugly Of COVID-19 Vaccine Manufacturing Technology Platforms

Not all technology platforms provide the expected benefit of filling in CMC review gaps and speeding coronavirus vaccine approvals.

SparingVision Raises €44.5m For Mutation-Agnostic Eye Gene Therapy

A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts